Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$0.98 -8.0%	$0.88	$0.66 ▼ $3.00	$90.68M	2.36	1.46 million shs	2.35 million shs
CYTH Cyclo Therapeutics	$0.72	$0.72	$0.55 ▼ $1.45	$23.72M	-0.57	490,392 shs	N/A
HLVX HilleVax	$1.93 +2.9%	$1.75	$1.34 ▼ $15.60	$96.52M	0.78	447,157 shs	123,741 shs
LXEO Lexeo Therapeutics	$2.73 +0.2%	$3.03	$1.45 ▼ $19.50	$90.46M	1.27	501,699 shs	299,223 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	0.00%	+5.39%	+22.16%	+0.47%	-62.67%
CYTH Cyclo Therapeutics	0.00%	0.00%	0.00%	-4.05%	-43.70%
HLVX HilleVax	0.00%	-0.81%	-5.87%	+5.43%	-84.80%
LXEO Lexeo Therapeutics	0.00%	-2.13%	-40.52%	+17.95%	-83.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBU Caribou Biosciences	2.3771 of 5 stars	3.5	1.0	0.0	0.0	2.2	3.3	0.6
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	2.4493 of 5 stars	3.0	1.0	0.0	0.0	2.7	3.3	1.3
LXEO Lexeo Therapeutics	3.8581 of 5 stars	4.6	3.0	0.0	0.0	2.5	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBU Caribou Biosciences	3.00	Buy	$7.40	658.97% Upside
CYTH Cyclo Therapeutics	2.33	Hold	$0.95	31.83% Upside
HLVX HilleVax	2.00	Hold	$3.00	55.84% Upside
LXEO Lexeo Therapeutics	3.14	Buy	$18.50	578.90% Upside

Current Analyst Ratings Breakdown

Latest CYTH, CRBU, LXEO, and HLVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
4/28/2025	CRBU Caribou Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $3.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/31/2025	HLVX HilleVax	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00
3/26/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/25/2025	LXEO Lexeo Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00
3/25/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/24/2025	LXEO Lexeo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $18.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBU Caribou Biosciences	$9.92M	9.14	N/A	N/A	$4.17 per share	0.23
CYTH Cyclo Therapeutics	$870.73K	27.24	N/A	N/A	$0.21 per share	3.43
HLVX HilleVax	N/A	N/A	N/A	N/A	$5.48 per share	N/A
LXEO Lexeo Therapeutics	$650K	139.17	N/A	N/A	$4.26 per share	0.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBU Caribou Biosciences	-$102.07M	-$1.62	N/A	N/A	N/A	-1,290.81%	-45.46%	-38.07%	8/5/2025 (Estimated)
CYTH Cyclo Therapeutics	-$20.06M	-$0.90	N/A	N/A	N/A	-2,847.19%	N/A	-307.16%	N/A
HLVX HilleVax	-$123.57M	-$2.15	N/A	N/A	N/A	N/A	-67.27%	-51.99%	8/7/2025 (Estimated)
LXEO Lexeo Therapeutics	-$66.39M	-$3.30	N/A	N/A	N/A	N/A	-57.66%	-48.18%	8/11/2025 (Estimated)

Latest CYTH, CRBU, LXEO, and HLVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/8/2025	Q1 2025	CRBU Caribou Biosciences	-$0.43	-$0.43	N/A	-$0.43	$1.48 million	$2.35 million
5/8/2025	Q1 2025	HLVX HilleVax	-$0.37	-$0.12	+$0.25	-$0.12	N/A	N/A
3/28/2025	Q4 2024	HLVX HilleVax	-$0.33	-$0.35	-$0.02	-$0.68	N/A	N/A
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A
3/10/2025	Q4 2024	CRBU Caribou Biosciences	-$0.40	-$0.39	+$0.01	-$0.39	$2.11 million	$2.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBU Caribou Biosciences	N/A	7.38	7.38
CYTH Cyclo Therapeutics	N/A	0.17	0.16
HLVX HilleVax	N/A	14.25	14.25
LXEO Lexeo Therapeutics	0.01	5.95	5.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBU Caribou Biosciences	77.51%
CYTH Cyclo Therapeutics	68.55%
HLVX HilleVax	86.42%
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
CRBU Caribou Biosciences	8.28%
CYTH Cyclo Therapeutics	29.78%
HLVX HilleVax	24.90%
LXEO Lexeo Therapeutics	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBU Caribou Biosciences	100	93.01 million	81.95 million	Optionable
CYTH Cyclo Therapeutics	9	32.92 million	23.12 million	No Data
HLVX HilleVax	20	50.14 million	14.39 million	Not Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.58 million	Not Optionable

CYTH, CRBU, LXEO, and HLVX Headlines

Recent News About These Companies

JPMorgan Chase & Co. Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

June 1 at 3:06 AM | americanbankingnews.com

Leerink Partnrs Has Optimistic Outlook of LXEO Q2 Earnings

June 1 at 1:23 AM | americanbankingnews.com

Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $10.00 at JPMorgan Chase & Co.

May 31 at 11:02 AM | marketbeat.com

Leerink Partnrs Issues Positive Forecast for LXEO Earnings

May 31 at 5:52 AM | marketbeat.com

Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares

May 29, 2025 | nasdaq.com

Lexeo raises $80 million to shore up gene therapy work after layoffs

May 28, 2025 | thepharmaletter.com

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

May 27, 2025 | globenewswire.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Buy" by Brokerages

May 24, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Trims Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

May 23, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Holdings Lifted by Point72 Asset Management L.P.

May 22, 2025 | marketbeat.com

Vestal Point Capital LP Raises Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

May 21, 2025 | marketbeat.com

Q1 Earnings Forecast for LXEO Issued By HC Wainwright

May 21, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Lifted by Janus Henderson Group PLC

May 17, 2025 | marketbeat.com

Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating

May 16, 2025 | tipranks.com

Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.61%

May 15, 2025 | aaii.com

Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

May 15, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Omega Fund Management LLC

May 15, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Misses Expectations By $0.19 EPS

May 14, 2025 | marketbeat.com

Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies

May 12, 2025 | fiercebiotech.com

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

May 12, 2025 | globenewswire.com

DAFNA Capital Management LLC Purchases 142,500 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

May 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTH, CRBU, LXEO, and HLVX Company Descriptions

Caribou Biosciences NASDAQ:CRBU

$0.98 -0.09 (-8.02%)

Closing price 03:59 PM Eastern

Extended Trading

$1.02 +0.05 (+4.62%)

As of 04:05 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Cyclo Therapeutics NASDAQ:CYTH

$0.72 0.00 (0.00%)

As of 03/26/2025

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

HilleVax NASDAQ:HLVX

$1.92 +0.06 (+2.94%)

Closing price 03:59 PM Eastern

Extended Trading

$1.92 0.00 (0.00%)

As of 04:04 PM Eastern

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$2.72 +0.01 (+0.18%)

Closing price 03:59 PM Eastern

Extended Trading

$2.73 +0.00 (+0.18%)

As of 04:04 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time